Kogenate FS
Potential health benefits   2008
Popular Search
Abilify
Accutane
Actonel
Actoplus
Actos
AcuTect
Adderall
Agenerase
Aggrastat
Alamast
Alimta
Alinia
Aloxi
Alrex
Ambien CR
Amerge
Amidarone
Amphadase
Antagon
Apidra
Apokyn
Aptivus
Arava
Arqatroban
Aripiprazole
Avanafil
Arixtra
Aromasin
Arranon
Asmanex
Atacand
Avandia
Avastin
Banzel
Duodote
Erbitux
Gardasil
GDNF
Ghrelin
GRN163
Herceptin
Increlex
Keppra
Kogenate FS
Levemir
Levothyroxine
Liraqlutide
Lithium
Carbonate
Lucentis
Lyrica
Omnitrope
Prezista
PSN010
PX12
Rapaflo
Remicade
Revlimid
Rozerem
Sorafenib
Sutent
Tamsulosin
Tapentadol HCL
Torcetrapib
Toviaz
Tykerb
Tysabri
Vectibix
Xeloda
Zoledronic acid
ALL RIGHTS RESERVED ZHION 2008. DO NOT TRANSFER THIS ARTICLE TO OTHER
WEBSITES OR BLOGS. CONSULT WITH YOUR DOCTOR FOR ANY QUESTION OR BEFORE
TAKING ANY SUPPLEMENT OR MEDICINE. THIS ARTICLE IS FOR YOUR REFERENCE ONLY.
APPROVAL / USE / INDICATIONS

The U.S. Food and Drug Administration on October 10 2008 approved a new use for
the blood product Kogenate FS to reduce the frequency of bleeding episodes and
prevent joint damage in children with the most severe form of hemophilia.

STRENGTHS

-

MECHANISM

Hemophilia A is a rare, hereditary, bleeding disorder in which a protein needed to
form blood clots, factor VIII, is missing or its level is reduced. The disorder affects
about 15,000 individuals in the United States, nearly all of whom are male.

When individuals with hemophilia are injured, they bleed longer than a person
without hemophilia. As a result, these individuals may experience serious bleeding
episodes, often in the joints and muscles. Repeated bleedings increase the chance
of joint damage.

Kogenate FS is a genetically engineered version of factor VIII. It was first licensed in
the United States in 1993 for use during surgery and to prevent or control other
bleeding episodes.

In a clinical trial, 65 boys under 30 months of age with severe hemophilia A and
normal joints were observed for five years. The patients received either one daily
dose of the drug, or three doses at the time of a bleeding episode. Joint damage
during a bleeding episode was 6-fold lower, and the rate of bleeding 8-fold lower, in
those boys who received the drug on a daily basis compared to those who received
the drug only when a bleeding episode occurred. Most patients received the drug
intravenously through a catheter.

COMMON SIDE EFFECTS / SAFETY ISSUES / CONTRAINDICATION

The most common adverse events were infection at the catheter site and fever.

MANUFACTURER

Kogenate FS is manufactured by Bayer Healthcare LLC, Tarrytown, N.Y.

SALES/MARKET/COMPETITION

-

Reference
[1] FDA News 2008